Sign In
Buy IOBCF
Ion Beam Applications S.A Earnings Calls
| Release date | Aug 27, 2025 |
| EPS estimate | - |
| EPS actual | -$0.106 |
| Revenue estimate | - |
| Revenue actual | 359.169M |
| Release date | May 21, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | May 22, 2025 |
| EPS estimate | $0.600 |
| EPS actual | $0.679 |
| EPS Surprise | 13.17% |
| Revenue estimate | 253.629M |
| Revenue actual | 302.058M |
| Revenue Surprise | 19.09% |
| Release date | Nov 21, 2024 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
Last 4 Quarters for Ion Beam Applications S.A
Below you can see how IOBCF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Nov 21, 2024 |
| Price on release | $13.80 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Nov 15, 2024 | $13.80 |
| Nov 18, 2024 | $13.80 |
| Nov 19, 2024 | $13.80 |
| Nov 20, 2024 | $13.80 |
| Nov 21, 2024 | $13.80 |
| Nov 22, 2024 | $13.80 |
| Nov 25, 2024 | $13.80 |
| Nov 26, 2024 | $13.99 |
| Nov 27, 2024 | $14.85 |
| 4 days before | 0% |
| 4 days after | 7.61% |
| On release day | 0% |
| Change in period | 7.61% |
| Release date | May 22, 2025 |
| Price on release | $13.25 |
| EPS estimate | $0.600 |
| EPS actual | $0.679 |
| EPS surprise | 13.17% |
| Date | Price |
|---|---|
| May 16, 2025 | $11.50 |
| May 19, 2025 | $13.25 |
| May 20, 2025 | $13.25 |
| May 21, 2025 | $13.25 |
| May 22, 2025 | $13.25 |
| May 23, 2025 | $13.00 |
| May 27, 2025 | $13.80 |
| May 28, 2025 | $13.80 |
| May 29, 2025 | $13.80 |
| 4 days before | 15.22% |
| 4 days after | 4.15% |
| On release day | -1.89% |
| Change in period | 20.00% |
| Release date | May 21, 2025 |
| Price on release | $13.25 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| May 15, 2025 | $12.75 |
| May 16, 2025 | $11.50 |
| May 19, 2025 | $13.25 |
| May 20, 2025 | $13.25 |
| May 21, 2025 | $13.25 |
| May 22, 2025 | $13.25 |
| May 23, 2025 | $13.00 |
| May 27, 2025 | $13.80 |
| May 28, 2025 | $13.80 |
| 4 days before | 3.92% |
| 4 days after | 4.15% |
| On release day | 0% |
| Change in period | 8.24% |
| Release date | Aug 27, 2025 |
| Price on release | $13.25 |
| EPS estimate | - |
| EPS actual | -$0.106 |
| Date | Price |
|---|---|
| Aug 21, 2025 | $13.25 |
| Aug 22, 2025 | $13.25 |
| Aug 25, 2025 | $13.25 |
| Aug 26, 2025 | $13.25 |
| Aug 27, 2025 | $13.25 |
| Aug 28, 2025 | $13.88 |
| Aug 29, 2025 | $13.95 |
| Sep 02, 2025 | $13.95 |
| Sep 03, 2025 | $13.95 |
| 4 days before | 0% |
| 4 days after | 5.28% |
| On release day | 4.72% |
| Change in period | 5.28% |
Ion Beam Applications S.A Earnings Call Transcript Summary of Q2 2025
Key points for investors:
- Strong top-line growth: Group revenue rose 40% y/y to EUR 304.9m in H1 2025, driven by accelerated backlog conversion across IBA Clinical (Proton Therapy & Dosimetry) and IBA Technologies. Technologies net sales grew ~30% to EUR 115m.
- Profitability improvement but mixed margins: Gross profit was EUR 90m (29.5% margin, down from 32.6% in H1 2024) due to legacy lower-margin Proton Therapy projects and some customer delays. REBIT improved to EUR 10.6m (Technologies REBIT ~EUR 13.1m; Dosimetry REBIT doubled to EUR 2.3m). Group net loss of EUR 2.6m driven by below-REBIT items.
- Guidance and outlook: Management reaffirms 2025 guidance of a minimum EUR 25m REBIT (with Proton Therapy returning to positive REBIT). H2 is expected to be stronger than H1, though more balanced than in 2024.
- Backlog, orders and backlog conversion: Backlog fell to ~EUR 1.3bn (from an all-time high EUR 1.5bn) due to strong conversion. H1 order intake was ~EUR 107m; post-period orders (incl. Heidelberg and two ProteusONE) bring intake close to ~EUR 190m.
- Proton Therapy operational progress: Increased installations (9 systems under installation), record delivery run (12 systems in 2025), continued market leadership with the largest installed base, service revenue representing ~40% of Proton Therapy top line. FDA submission for DynamicARC is on track before commercial release in 2027.
- Geopolitical and market risks: US tariffs (15% on EU imports without medical-device exemptions) are expected to have marginal impact on equipment profitability and negligible effect on services; China introduced restrictions on large medical device purchases from European origin (affecting single-room ProteusONE), prompting mitigation plans (exemptions, local partnerships, local sourcing). Management treats China single-room sales as upside to guidance.
- Corporate/new ventures: PanTera began small-batch actinium production and secured permits; the third tranche release caused a EUR 7.2m revaluation gain for IBA (shareholding diluted to 34.8%). Normandy Hadrontherapy progress de‑risked but requires refinancing; IBA has provided bridge financing.
- Cash and liquidity: Accelerated backlog conversion created a working-capital peak (contract assets / advanced billing ~EUR 90m impact). Net debt reached ~EUR 30m and net leverage ~0.62. Management used revolving credit up to EUR 30m at end-June and tactically increased credit lines from EUR 60m to EUR 80m in July. Expect working-capital normalization as large Spanish and Chinese projects are delivered, with improvements into 2026.
- Cost control and efficiency: OpEx at 26% of sales (below the 30% long-term target). Management identified specific savings in services, R&D productivity and indirect OpEx to support margin expansion and included these in guidance.
Overall: The company delivered strong execution and revenue growth, with improving REBIT but temporary working-capital pressure and some legacy lower-margin project effects on gross margin. Management maintained full-year guidance (>= EUR 25m REBIT), emphasized liquidity steps, and highlighted technology/market milestones (DynamicARC, ProteusONE, PanTera) that underpin medium-term upside.
